Toggle menu

HOME
ABOUT US
TECHNOLOGIES
- Our Technologies
- PIPELINE
INVESTORS
MEDIA
- Media
- Briefing recordings
CONTACT US

HOME
ABOUT US
TECHNOLOGIES
- Our Technologies
- PIPELINE
INVESTORS
MEDIA
- Media
- Briefing recordings
CONTACT US

Blog Post

Home > Webcast Video > The Future of Medicine is Personal

The Future of Medicine is Personal

August 7, 2019 AUTHOR – enouvoteam

Webcast Video 0

Share

306 / 305

Related Posts

Prescient Therapeutics (ASX:PTX) precision oncology medicine

Webcast Video 0

Summary of recent major announcements

News, Webcast Video 0

Tom Long

Webcast Video 0

ASX ANNOUNCEMENTS

RECENT POSTS

Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials

Prescient Therapeutics welcomes US FDA allowance of Investigational New Drug application for PTX-100 Phase 2 clinical trial

Prescient Therapeutics appoints experienced pharmaceuticals executive James McDonnell as CEO

Categories

Article (106)106
Media (13)13
News (305)305
Uncategorized (1)1
Webcast Video (7)7

Tags

AusBiz Biotech Dispatch BioWorld CGT Live Global Victoria Investing Kalkine Kalkine Media Market Herald Market Open Mirage News National Tribune Pitt Street Research Port Jackson Securities Prescient Therapeutics Proactive Investors Reach Markets ShareCafe Share Cafe Small Caps Smallcaps Stockhead Sub11 Switzer TechKnow Invest Roadshow The Australian The Australian Business Review The Market Herald The Sentiment Yahoo Finance

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cell therapies.

CONTACT

P: +61 3 9692 7222

F: +61 3 9077 9233

E: admin@ptxtherapeutics.com

ABOUT

TECHNOLOGIES

PIPELINE

INVESTORS

This Investor Centre was built by Reach Markets.
Visit Reach Markets here

©2023 REACH MARKETS

×

Do you qualify as a Wholesale (708) investor?

Wholesale 708 Sophisticated Investors are individuals or entities who generally qualify under Sections 708(8) and s761G(7) of the Corporations Act based on the gross income and/or net assets test verified by a qualified accountant.

A gross income of $250,000 or more per annum in each of the previous two financial years; or
Net assets of at least $2.5 million; and
A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)

preload image

preload image

Subscribe for updates

First name*

Last name*

Email*

Phone number*

State

Are You A Company Shareholder?

Yes
No

Are You A Wholesale (708) Investor?

Yes
No

EC Submit

What is a 708 investor?

By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach Corporate provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.